Neogen Chemicals Ltd
Neogen Chemicals Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
FY27 and FY28 are expected to see double-digit revenue growth in the base business, especially post the Dahej plant ramp-up. Neogen Chemicals expects steady revenue growth driven by the ramp-up of battery chemicals, including electrolyte and salts production at the Dahej and Pakhajan plants.
From Neogen Chemicals Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- FY27 and FY28 are expected to see double-digit revenue growth in the base business, especially post the Dahej plant ramp-up.
- Battery chemicals segment projected to generate INR 400-500 crore revenue in FY27, considering limited salt sales from Pakhajan in H2 FY27.
- Electrolyte revenues are expected to increase in H2 FY27 due to capacity ramps by major customers like Ola, Exide, and Waaree.
- The Pakhajan salt plant’s full 30,000 MT capacity is targeted to be operational by end of H1 FY27, with gradual ramp-up based on business visibility.
- By end of 2027, India's battery cell manufacturing capacity expected to reach 40-50 GWh with new and expanding capacities.
2 more points from Neogen Chemicals Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Neogen Chemicals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Neogen Chemicals is progressing with the Pakhajan greenfield project, targeting:
- Electrolyte commercial production in H1 FY27.
- Electrolyte salts production in H2 FY27.
- Equipment arrival and assembly underway; trial production expected soon.
- Rebuilding and expansion of the Dahej plant ongoing, with completion and commissioning expected by Q1 FY27 and capacity ramp-up by March 2026.
- Preferential equity infusion planned from Promoter Group of INR 150 crore by March 2026 to support growth and reduce interest burden.
- Joint venture with Morita Investment Ltd for LiPF6 salt production, with $20 million investment for 20% stake, expected receipt by Q1 FY27.
2 more points from Neogen Chemicals Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Neogen Chemicals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Salt business has shown increased interest with many regular and non-regular customers.
- Majority of requirements for one key customer are complete, with final approval timelines expected by Q1 FY27.
- Three to four other customers have started sampling and approving, with audits planned between March and May 2026.
- Dahej site approval expected by June 2026; sales to start progressively from Q2 FY27 onwards.
- Pakhajan site target approval by September 2026, with trial production starting in H2 FY27 and sales from Q4 FY27.
- Significant inquiries for lithium salts and intermediates due to regulatory changes and demand growth.
2 more points from Neogen Chemicals Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Neogen Chemicals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹247 Cr, net profit ₹11 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Neogen Chemicals Ltd's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Neochem Bio Solutions Ltd (Q3 FY26)
Revenue for Q2 FY26 (Sept’25) stood at ₹4,583.16 Lakh. Key investor presentation takeaways from Neochem Bio Solutions Ltd's Q3 FY26 investor presentation — and
- Thirumalai Chemicals Ltd (Q3 FY26)
Q3 FY26 Revenue from Operations (INR Cr):** . Key investor presentation takeaways from Thirumalai Chemicals Ltd's Q3 FY26 investor presentation — and how it ran
- Jubilant Agri & Consumer Products Ltd (Q3 FY26)
Q3 FY26 Revenue from Operations: INR 4,510 million, up 13% YoY from INR 3,975 million in Q3 FY25 (Page 20). Key investor presentation takeaways from Jubilant Ag
- Chemfab Alka. (Q3 FY26)
Revenue from Operation: ₹62.17 crore, down 21.51% YoY (₹79.21 crore in Q3FY25) . Key investor presentation takeaways from Chemfab Alka.'s Q3 FY26 investor prese
Arthneeti Pro · Annual
Neogen Chemicals Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Neogen Chemicals Ltd Q3 FY26 results?
FY27 and FY28 are expected to see double-digit revenue growth in the base business, especially post the Dahej plant ramp-up. Neogen Chemicals expects steady revenue growth driven by the ramp-up of battery chemicals, including electrolyte and salts production at the Dahej and Pakhajan plants.
What is Neogen Chemicals Ltd share price analysis?
Neogen Chemicals Ltd currently shows a neutral. The stock trades at a P/E of 155.0 with a market cap of ₹5,511 Cr. Investors should review the full earnings analysis for detailed insights.
Is Neogen Chemicals Ltd planning capital expenditure?
Neogen Chemicals is progressing with the Pakhajan greenfield project, targeting: - Electrolyte commercial production in H1 FY27.
Keep Neogen Chemicals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.